# Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept

Study · id `cardio:ct-nct03312855` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03312855](<https://clinicaltrials.gov/study/NCT03312855>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03312855

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 334 participants.

## Technical summary

Registry record NCT03312855. Randomized; quadruple masking; primary purpose treatment. Start 2017-11-20 (actual); primary completion 2020-02-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 334 participants (enrolled count; ClinicalTrials.gov record NCT03312855, source copy `cardio:ctgov-nct03312855-2020-04-20`, retrieved 2026-10-26)
- Started: 2017-11-20 (actual) (ClinicalTrials.gov record NCT03312855, source copy `cardio:ctgov-nct03312855-2020-04-20`, retrieved 2026-10-26)
- Primary completion: 2020-02-29 (actual) (ClinicalTrials.gov record NCT03312855, source copy `cardio:ctgov-nct03312855-2020-04-20`, retrieved 2026-10-26)
- Completion: 2020-03-26 (actual) (ClinicalTrials.gov record NCT03312855, source copy `cardio:ctgov-nct03312855-2020-04-20`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT03312855, source copy `cardio:ctgov-nct03312855-2020-04-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03312855-2020-04-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept
- Acronym: ISAR-PLASTER
- Condition: Stable Coronary Artery Disease
- Intervention (Drug): Revacept 80 mg
- Intervention (Drug): Revacept 160 mg
- Intervention (Drug): Placebo
- Lead sponsor: Deutsches Herzzentrum Muenchen
- Lead sponsor class: OTHER
- Collaborator: Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
- Collaborator class: OTHER
- Collaborator: AdvanceCor GmbH
- Collaborator class: INDUSTRY
- Collaborator: Technical University of Munich
- Collaborator class: OTHER
- Collaborator: German Federal Ministry of Education and Research
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Deutsches Herzzentrum Muenchen (`cardio:org-deutsches-herzzentrum-muenchen`)
- Registry lists this organization as a collaborator: Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) (`cardio:org-deutsches-zentrum-fur-herz-kreislauf-forschung-dzhk`)
- Registry lists this organization as a collaborator: Technical University of Munich (`cardio:org-technical-university-of-munich`)
- Registry lists this organization as a collaborator: German Federal Ministry of Education and Research (`cardio:org-german-federal-ministry-of-education-and-research`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial (`cardio:pubmed-33787834`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 6fb2394c3b9a0e6eed8f7d53a7db7327d60a890ec7b663907c082c9a2c192ea9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
